§ 522.150 Azaperone.

(a) Specifications. Each milliliter of solution contains 40 milligrams (mg) azaperone.

(b) Sponsor. See No. 012578 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For control of aggressiveness when mixing or regrouping weanling or feeder pigs weighing up to 80 pounds.

(2) Dosage. 2.2 mg per kilogram (1 mg per pound) by deep intramuscular injection.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[74 FR 65689, Dec. 11, 2009]

§ 522.161 Betamethasone acetate and betamethasone disodium phosphate aqueous suspension.


(b) Specifications. The drug is a sterile aqueous suspension and each cubic centimeter contains: 12 milligrams of betamethasone acetate (equivalent to 10.8 milligrams of betamethasone), 3.9 milligrams of betamethasone disodium phosphate (equivalent to 3 milligrams of betamethasone), 2 milligrams of dibasic sodium phosphate, 5 milligrams of sodium chloride, 0.1 milligram of disodium EDTA, 0.5 milligram of polysorbate 80, 9 milligrams of benzyl alcohol, 5 milligrams of sodium carboxymethylcellulose, 1.8 milligrams of methylparaben, 0.2 milligram of propylparaben, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection q.s.

(c) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(2) Conditions of use. It is used or intended for use by intra-articular injection of horses for the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and fetlock joints. Administer from 2.5 to 5 cubic centimeters per dose. Dose may be repeated when necessary depending upon the duration of relief obtained. Not for use in horses intended for food. For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7632, Mar. 13, 1987]
corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(4) Restrictions. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.204 Boldenone.

(a) Specifications. Each milliliter of solution contains 25 or 50 milligrams (mg) boldenone undecylenate.

(b) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 0.5 mg per pound body weight by intramuscular injection. Treatment may be repeated at 3-week intervals.

(2) Indications for use. As an aid for treating debilitated horses when an improvement in weight, hair coat, or general physical condition is desired.

(3) Limitations. Do not administer to horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.234 Butamisole hydrochloride.

(a) Specifications. The drug contains 11 milligrams of butamisole per milliliter in a solution consisting of 70 percent propylene glycol, 4 percent benzyl alcohol and distilled water.

(b) Sponsor. See Nos. 000859 and 053501 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is administered by subcutaneous injection to dogs for the treatment of infections with whipworms (Trichuris vulpis), and the hookworm (Ancylostoma caninum).

(2) The drug is administered subcutaneously at the rate of 0.1 milliliter per pound of body weight. In problem cases, retreatment for whipworms may be necessary in approximately 3 months. For hookworms, a second injection should be given 21 days after the initial treatment.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.246 Butorphanol.

(a) Specifications. Each milliliter of solution contains butorphanol (as butorphanol tartrate) in the following amounts:

(1) 0.5 milligrams (mg);

(2) 2 mg; or

(3) 10 mg

(b) Sponsors. See sponsors in §510.600(c) of this chapter as follows:

(1) No. 000856 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section; for use of the product described in paragraph (a)(2) as in paragraph (d)(2) of this section; and for use of the product described in paragraph (a)(3) as in paragraph (d)(3) of this section.

(2) No. 059130 for use of the product described in paragraph (a)(2) as in paragraph (d)(2) of this section.

(3) Nos. 000061, 059130, and 061690 for use of the product described in paragraph (a)(3) as in paragraph (d)(3) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs—(i) Amount. Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days.

(ii) Indications for use. For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.

(2) Cats—(i) Amount. Administer 0.2 mg per pound of body weight by subcutaneous injection. Dose may be repeated up to 4 times per day. Do not treat for more than 2 days.

(ii) Indications for use. For the relief of pain in cats caused by major or